FDA Updates Category 2 Restricted Peptide List Following Withdrawn Nominations
Key Takeaways
- FDA announced on April 15, 2026, that **12 peptide bulk drug substances** will be removed from Category 2 after 7 days due to withdrawn nominations
- **Removal from Category 2 does not automatically authorize compounding** — peptides remain in regulatory limbo until PCAC review
- **PCAC meetings scheduled for July 23-24, 2026** will evaluate seven peptides for potential 503A bulks list inclusion
- **Affected peptides include** BPC-157, TB-500, MOTS-C, GHK-Cu (injectable), Melanotan II, Semax, and others
- This represents a **procedural change, not regulatory clearance** for peptide compounding
Background: FDA Category System Overview
The FDA’s interim policy for bulk drug substances under Section 503A operates through a three-tier categorization system that governs what compounds may be legally used in pharmacy compounding:
Category 1
May Be Compounded
Substances under evaluation with adequate supporting information and no significant safety risks identified. FDA exercises enforcement discretion for these compounds.
Category 2
Restricted – Safety Concerns
Substances with sufficient information but significant safety risks identified pending further evaluation. Compounding prohibited.
Category 3
Insufficient Information
Substances with insufficient supporting information, indicating need for more research or data.
The April 15 Regulatory Update
On April 15, 2026, the FDA announced a major shift in the regulatory landscape for compounded peptides, updating its Bulk Drug Substances list and removing 12 peptide substances from Category 2 due to withdrawn nominations.
Critical Distinction: Removal from Category 2 does not, by itself, place these substances on the 503A bulks list or into Category 1 for which FDA is exercising enforcement discretion.
Affected Peptides
The complete list of peptides being removed from Category 2 includes:
| Peptide | PCAC Review Timeline | Primary Research Applications |
|---|---|---|
| BPC-157 | July 2026 | Tissue repair, gut healing, reducing inflammation |
| TB-500 (Thymosin β4) | July 2026 | Wound healing, tissue regeneration |
| Semax | July 2026 | Neuroprotection, cognitive enhancement |
| Epitalon | July 2026 | Anti-aging, cellular repair |
| MOTS-C | July 2026 | Metabolic regulation |
| KPV | July 2026 | Anti-inflammatory |
| Emideltide (DSIP) | July 2026 | Sleep regulation |
| Cathelicidin LL-37 | Before Feb 2027 | Antimicrobial, wound healing |
| Dihexa Acetate | Before Feb 2027 | Cognitive enhancement |
| GHK-Cu (injectable) | Before Feb 2027 | Anti-aging, wound healing |
| PEG-MGF | Before Feb 2027 | Muscle growth, recovery |
| Melanotan II | Before Feb 2027 | Tanning, libido |
PCAC Review Process
The Pharmacy Compounding Advisory Committee (PCAC) is an independent advisory body that provides recommendations to the FDA on matters related to pharmaceutical compounding, with its primary function being to evaluate substances nominated for inclusion on the Section 503A Bulk Drug Substances List.
A public docket (Docket No. FDA-2025-N-6895) has been established for comments related to the review, allowing stakeholder input on the evaluation process.
Regulatory Limbo and Market Implications
The peptides will exist in a regulatory gray area until the PCAC meets and the FDA takes final action. Compounding pharmacies should still exercise caution regarding these peptides until their status is determined by FDA.
What This Change Does NOT Mean
This regulatory change is not the same as FDA approval. Removal from Category 2 is a step, not a clearance.
What Happens Next
The FDA still has specific criteria a substance must meet to be eligible for compounding, and the PCAC’s review will determine whether any of these peptides will be officially cleared.
Industry Caution: The announcement does not indicate that peptides will be placed on the Category 1 “May Compound” list, possibly leaving those bulk drug substances in limbo unless the FDA announces enforcement discretion.
Historical Context
In late 2023, the FDA moved 19 widely used peptides to its Category 2 list, effectively banning compounding pharmacies from preparing them due to safety concerns such as immunogenicity, manufacturing impurities, and insufficient human clinical data.
There is precedent from the Biden administration when several peptides previously on the Category 2 list were similarly withdrawn by nominators and removed, then brought before the PCAC, which recommended against inclusion on the 503A bulks list in each case.
Research-Grade Supply Considerations
For research institutions and laboratories requiring these compounds for legitimate scientific research, this regulatory shift creates both opportunities and challenges:
- Quality Assurance: To comply with section 503A, pharmacies will need to source pharmaceutical-grade API from FDA-registered manufacturers, accompanied by valid certificates of analysis
- Documentation Requirements: Enhanced documentation standards will be required for any approved compounds
- Supply Chain Impact: Current research-grade suppliers must navigate the evolving regulatory landscape carefully
Research Impact: While this development may eventually improve access to research-grade peptides, the interim period requires careful attention to regulatory compliance and sourcing protocols.
Sources
- Orrick, Herrington & Sutcliffe LLP – FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings. orrick.com/en/Insights/2026/04/FDA-Announces-Removal-of-12-Peptides-from-Category-2-and-Schedules-PCAC-Meetings
- Frier Levitt – FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List. frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/
- American Med Spa Association – FDA Moves to Reevaluate Several Peptides. americanmedspa.org/news/fda-moves-to-reevaluate-several-peptides/
- FDA – Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
Last updated: May 18, 2026
Neogenesis BioLabs remains committed to providing the highest quality research-grade compounds while maintaining full regulatory compliance throughout this evolving landscape.